A PHASE 1, OPEN-LABEL, RANDOMIZED CROSSOVER STUDY TO COMPARE THE SINGLE-DOSE PHARMACOKINETICS OF TWO FORMULATIONS OF PF-07976016 ADMINISTERED ORALLY TO HEALTHY ADULT PARTICIPANTS
Latest Information Update: 14 Nov 2024
Price :
$35 *
At a glance
- Drugs PF 07976016 (Primary)
- Indications Obesity
- Focus Pharmacokinetics
- Sponsors Pfizer
- 11 Nov 2024 Status changed from not yet recruiting to recruiting.
- 04 Nov 2024 New trial record